Welcome!

News Feed Item

Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation



 

 

 

 

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation


Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation

Summary

GBI Research has released its pharmaceuticals report, "Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation". The Alzheimer's Disease (AD) market is characterized by a lack of products with strong disease-modifying properties and a number of high-profile product failures in late stages of development over recent years. In addition, recent or impending patent expiries for all of the four currently marketed products and a late-stage pipeline with limited-to-moderate prospects are expected to impede growth over the next few years. In the medium-term future, the market is expected to be characterized by substantial generic competition and overall decline. However, the current development pipeline shows signs of meaningful innovation, although the vast majority of these products are currently in the early stages of development. Despite one of the highest drug attrition rates across the industry, a number of innovative and potentially disease-modifying therapeutics are likely to enter the market and translate recent insights into the etiology of AD combined with an earlier therapeutic intervention into better products, which will begin to transform the AD market towards the end of the decade.


Scope

- A brief introduction to AD etiology, pathogenesis, diagnosis, and treatment regimes
- Profiling of the marketed products in the AD market, including analysis of their safety, efficacy, treatment patterns, and strengths and weaknesses
- Comprehensive review of the pipeline for AD therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule type, and molecular target.
- Additional in-depth analysis of pipeline drug clinical trials, analyzed by phase, molecule type, trial size, trial duration and program failure rate, for each molecule type and mechanism of action
- Multi-scenario forecast data for the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets of the US, Japan, Germany, the UK, France, Italy and Spain
- Discussion of the drivers of and barriers to market growth
- Analysis of the licensing and co-development deals landscape

Reasons to buy

- Understand the different levels of AD therapies, from early-stage or mild AD to severe AD
- Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent
- Observe trends in terms of clinical trial duration and size among clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for AD therapeutics
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the AD therapeutics market
Table of Contents

1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Symptoms 8
2.2 Etiology 9
2.3 Pathophysiology 10
2.3.1 Amyloidosis 10
2.3.2 Tau Hyperphosphorylation 10
2.4 Comorbidities/Complications 11
2.5 Diagnosis 11
2.5.1 Physical Examination 12
2.5.2 Mini Mental State Exam 12
2.5.3 Alzheimer's Disease Assessment Scale-cognitive 14
2.5.4 Alzheimer's Disease Co-operative Study – Activities of Daily Living Inventory 15
2.5.5 Other Diagnostic Tests 15
2.5.6 Blood Tests 15
2.5.7 Imaging Tests 15
2.5.8 Lumbar Puncture 15
2.5.9 Disease Biomarkers 16
2.5.10 Biomarker Market 17
2.6 Prognosis 18
2.7 Treatment Options 18
2.7.1 Treatment Algorithm 19
2.7.2 Non-Pharmacological Treatments 19
3 Marketed Products 20
3.1 Namenda/Axura/Memary (memantine), Merz Pharma/Lundbeck/Forest Laboratories/Daiichi Sankyo 20
3.2 Aricept (donepezil), Eisai Inc. 21
3.3 Exelon (rivastigmine), Novartis AG 22
3.4 Razadyne (galantamine), Janssen Pharmaceuticals 22
3.5 Cognex (tacrine), Shiniogi Inc. 23
3.6 Unmet Need 24
4 Pipeline for Alzheimer's Disease Therapeutics 25
4.1 Overall Pipeline 25
4.2 Mechanisms of Action within the AD Pipeline 27
4.3 Clinical Trials 29
4.3.1 Clinical Trial Failure Rate 29
4.3.2 Clinical Trial Size 33
4.3.3 Clinical Trial Duration 35
4.4 Notable Pipeline Drugs 38
4.4.1 Solanezumab – Eli Lilly and Company 38
4.4.2 LMTX (Methylene Blue) – TauRX Therapeutics Ltd. 39
4.4.3 RG-1540 (gantenerumab) – Roche 39
4.4.4 AD-02 – AFFiRiS AG 40
4.4.5 MK-8931 – Merck & Co. 41
4.4.6 CAD-106 – Novartis AG 41
4.4.7 LuAE58054 – Lundbeck 42
4.4.8 Crenezumab (RG7412) – Genentech 42
4.5 Conclusion 42
5 Market Forecast to 2019 44
5.1 Geographical Markets 44
5.1.1 Key Developed Markets 44
5.1.2 US 47
5.1.3 Leading Five EU Countries (EU5) 49
5.1.4 Japan 53
5.2 Drivers and Barriers 55
5.2.1 Drivers 55
5.2.2 Barriers 56
6 Deals and Strategic Consolidations 58
6.1 Key Licensing Deals 58
6.1.1 Forest Laboratories Inc. Enters into Agreement with Adamas Pharmaceuticals Inc. 60
6.1.2 AC Immune SA Enters into an Agreement with Genentech Inc. 60
6.1.3 Cephalon Inc. Enters into Agreement with Mesoblast Limited 60
6.1.4 Acadia Pharmaceuticals Inc. Enters into Agreement with Biovail Laboratories International SRL 60
6.1.5 Astellas Pharma Inc. enters into Agreement with CoMentis Inc. 61
6.2 Key Co-development Deals 61
6.2.1 Evotec AG Enters into Agreement with F. Hoffman-La Roche Ltd. 63
6.2.2 Alectos Therapeutics Inc. Enters into Agreement with Merck & Co. Inc. 63
6.2.3 Targacept Inc. Expands Agreement with AstraZeneca PLC. 63
6.2.4 GlaxoSmithKline Enters into an Agreement with Epix Pharmaceuticals 64
7 Appendix 65
7.1 All Pipeline Drugs by Phase – Tables 65
7.2 Market forecast to 2019 - Tables 81
7.3 References 84
7.4 Abbreviations 87
7.5 Methodology 89
7.6 Secondary Research 89
7.7 Therapeutic Landscape 90
7.8 Contact Us 90
7.9 Disclaimer 90



List of Tables


Table 1: Alzheimer's Disease, Global, All Pipeline Products (Discovery) 65
Table 2: Alzheimer's Disease, Global, All Pipeline Products (Preclinical) 68
Table 3: Alzheimer's Disease, Global, All Pipeline Products (Phase I) 76
Table 4: Alzheimer's Disease, Global, All Pipeline Products (Phase II) 79
Table 5: Alzheimer's Disease, Global, All Pipeline Products (Phase III) 81
Table 6: Alzheimer's Disease, Global, Market Forecast, 2012–2019 81
Table 7: Alzheimer's Disease, US, Market Forecast, 2012–2019 81
Table 8: Alzheimer's Disease, UK, Market Forecast, 2012–2019 82
Table 9: Alzheimer's Disease, France, Market Forecast, 2012–2019 82
Table 10: Alzheimer's Disease, Germany, Market Forecast, 2012–2019 82
Table 11: Alzheimer's Disease, Italy, Market Forecast, 2012–2019 83
Table 12: Alzheimer's Disease, Spain, Market Forecast, 2012–2019 83
Table 13: Alzheimer's Disease, Japan, Market Forecast, 2012–2019 83



List of Figures



Figure 1: Mini-Mental State Exam 13
Figure 2: Alzheimer's Disease Assessment Scale Cognitive Subscale 14
Figure 3: Alzheimer's Disease, Overall Pipeline 26
Figure 4: Alzheimer's Disease, Mechanisms of Action in the Pipeline, 2006–2013 29
Figure 5: Alzheimer's Disease, Failure Rates of Clinical Trials, 2006–2013 30
Figure 6: Alzheimer's Disease, Failure Rates by Mechanism of Action, 2006–2013 31
Figure 7: Alzheimer's Disease, Reasons for Clinical Trial Failure, 2006–2013 32
Figure 8: Alzheimer's Disease, Clinical Trial Size by Phase, 2006–2013 33
Figure 9: Alzheimer's Disease, Clinical Trial Size by Molecule Type, 2006–2013 34
Figure 10: Alzheimer's Disease, Clinical Trial Duration by Phase, 2006–2013 35
Figure 11: Alzheimer's Disease, Clinical Trial Duration by Molecule Type, 2006–2013 36
Figure 12: Alzheimer's Disease, Global, 2012–2019 46
Figure 13: Alzheimer's Disease, US, 2012–2019 48
Figure 14: Alzheimer's Disease, EU5, Patient Number ('000) 2012–2019 50
Figure 15: Alzheimer's Disease, EU5, Annual Cost of Treatment ($), 2012–2019 51
Figure 16: Alzheimer's Disease, EU5, Market Size ($m), 2012–2019 52
Figure 17: Alzheimer's Disease, Japan, 2012–2019 54
Figure 18: Alzheimer's Disease, Global, Licensing Deals by Region and Year, 2012–2019 58
Figure 19: Alzheimer's Disease, Global, Licensing Deals by Phase and Molecule Type, 2012–2019 59
Figure 20: Alzheimer's Disease, Global, Co-development Deals by Region and Year, 2012–2019 61
Figure 21: Alzheimer's Disease, Global, Co-development Deals by Phase and Molecule Type, 2006–2013 62


Read the full report:
Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation
http://www.reportbuyer.com/pharma_healthcare/treatments/alzheimers_disea...

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
"We're bringing out a new application monitoring system to the DevOps space. It manages large enterprise applications that are distributed throughout a node in many enterprises and we manage them as one collective," explained Kevin Barnes, President of eCube Systems, in this SYS-CON.tv interview at DevOps at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
The best-practices for building IoT applications with Go Code that attendees can use to build their own IoT applications. In his session at @ThingsExpo, Indraneel Mitra, Senior Solutions Architect & Technology Evangelist at Cognizant, provided valuable information and resources for both novice and experienced developers on how to get started with IoT and Golang in a day. He also provided information on how to use Intel Arduino Kit, Go Robotics API and AWS IoT stack to build an application tha...
IoT generates lots of temporal data. But how do you unlock its value? You need to discover patterns that are repeatable in vast quantities of data, understand their meaning, and implement scalable monitoring across multiple data streams in order to monetize the discoveries and insights. Motif discovery and deep learning platforms are emerging to visualize sensor data, to search for patterns and to build application that can monitor real time streams efficiently. In his session at @ThingsExpo, ...
Adding public cloud resources to an existing application can be a daunting process. The tools that you currently use to manage the software and hardware outside the cloud aren’t always the best tools to efficiently grow into the cloud. All of the major configuration management tools have cloud orchestration plugins that can be leveraged, but there are also cloud-native tools that can dramatically improve the efficiency of managing your application lifecycle. In his session at 18th Cloud Expo, ...
Ovum, a leading technology analyst firm, has published an in-depth report, Ovum Decision Matrix: Selecting a DevOps Release Management Solution, 2016–17. The report focuses on the automation aspects of DevOps, Release Management and compares solutions from the leading vendors.
Continuous testing helps bridge the gap between developing quickly and maintaining high quality products. But to implement continuous testing, CTOs must take a strategic approach to building a testing infrastructure and toolset that empowers their team to move fast. Download our guide to laying the groundwork for a scalable continuous testing strategy.
Choosing the right cloud for your workloads is a balancing act that can cost your organization time, money and aggravation - unless you get it right the first time. Economics, speed, performance, accessibility, administrative needs and security all play a vital role in dictating your approach to the cloud. Without knowing the right questions to ask, you could wind up paying for capacity you'll never need or underestimating the resources required to run your applications.
SYS-CON Events announced today that LeaseWeb USA, a cloud Infrastructure-as-a-Service (IaaS) provider, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. LeaseWeb is one of the world's largest hosting brands. The company helps customers define, develop and deploy IT infrastructure tailored to their exact business needs, by combining various kinds cloud solutions.
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
SYS-CON Events announced today that 910Telecom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and ...
StackIQ has announced the release of Stacki 3.2. Stacki is an easy-to-use Linux server provisioning tool. Stacki 3.2 delivers new capabilities that simplify the automation and integration of site-specific requirements. StackIQ is the commercial entity behind this open source bare metal provisioning tool. Since the release of Stacki in June of 2015, the Stacki core team has been focused on making the Community Edition meet the needs of members of the community, adding features and value, while ...
Big Data, cloud, analytics, contextual information, wearable tech, sensors, mobility, and WebRTC: together, these advances have created a perfect storm of technologies that are disrupting and transforming classic communications models and ecosystems. In his session at @ThingsExpo, Erik Perotti, Senior Manager of New Ventures on Plantronics’ Innovation team, provided an overview of this technological shift, including associated business and consumer communications impacts, and opportunities it ...
SYS-CON Events announced today that Venafi, the Immune System for the Internet™ and the leading provider of Next Generation Trust Protection, will exhibit at @DevOpsSummit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Venafi is the Immune System for the Internet™ that protects the foundation of all cybersecurity – cryptographic keys and digital certificates – so they can’t be misused by bad guys in attacks...